TOP

*Name

Phone

*Email

*Company/Institute

Consultation content

*Verification code

Contact Sales


Sales Image

Contact Sales Assistant


Sales Assistant Image

Contact PM


PM Image

Gene Synthesis Services

Oligonucleotide Service

Sanger Sequencing Service

Recombinant Protein Expression Service

Recombinant Antibody Expression Service

Pharmaceutical NGS Safety Testing Services

NGS Research and Technology Services

Gene Editing Services

Cell Therapy s Gene Therapy Antibody Drugs Nucleic Acid Drugs Synthetic Biology In Vitro Diagnosis

Application Area

Application Area

Cell Therapy Solutions

Cell Therapy Solutions

Gene Therapy

Gene Therapy

Antibody Drugs

Antibody Drugs

Nucleic Acid Drugs

Nucleic Acid Drugs

Synthetic Biology

Synthetic Biology

In Vitro Diagnosis

In Vitro Diagnosis

News and Events

News and Events

Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code

Company News

2025-04-24

Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code

On April 17, 2025, the International Institute of Molecular and Cell Biology in Warsaw, the University of Warsaw, the Medical University of Warsaw and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences jointly published in Nature, "Re-adenylation by TENT5A enh ances efficacy of SARS-CoV-2 mRNA vaccines" research has brought a new breakthrough to this problem - it is found that TENT5A polymerase can prolong the poly (A) tail of mRNA, stabilize mRNA and enhance immunity. The originality reveals the key mechanism of the efficacy of mRNA vaccine. The stability of mRNA molecules by TENT5A enzyme is a universal mechanism, so it has great potential in medicine.

View More

GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!

Company News

2024-11-04

GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!

RNAi is an intracellular post-transcriptional gene regulatory mechanism that was discovered in 1998 by Andrew Fire, Craig Mello and others in the Cryptomeria japonica nematode. It was shown that double-stranded RNA can trigger RNAi to catalyze the degradation of complementary mRNA transcripts in Cryptobacterium hidradii nematodes.Andrew Fire, Craig Mello won the Nobel Prize for this in 2006. After 20 years of technology development, the first siRNA drug was approved for marketing and clinical translation in 2018.

View More

Activities and Promotions

Activities and Promotions